Artivion (NYSE:AORT) Rating Lowered to “Hold” at Wall Street Zen

Artivion (NYSE:AORT) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC reissued a “buy” rating and set a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Citizens Jmp boosted their target price on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Canaccord Genuity Group decreased their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research report on Friday. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.69.

Artivion Stock Performance

Shares of AORT stock opened at $36.24 on Friday. The company has a market cap of $1.72 billion, a P/E ratio of 181.18 and a beta of 1.59. The business has a 50 day moving average of $43.60 and a two-hundred day moving average of $42.95. Artivion has a 52 week low of $21.97 and a 52 week high of $48.25. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. The business’s revenue for the quarter was up 19.2% on a year-over-year basis. As a group, analysts anticipate that Artivion will post 0.37 EPS for the current year.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 47,376 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $45.04, for a total value of $2,133,815.04. Following the completion of the sale, the senior vice president directly owned 44,753 shares in the company, valued at $2,015,675.12. This represents a 51.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO James P. Mackin sold 30,921 shares of the stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $45.56, for a total value of $1,408,760.76. Following the transaction, the chief executive officer directly owned 800,993 shares of the company’s stock, valued at approximately $36,493,241.08. The trade was a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 109,660 shares of company stock valued at $4,941,347. 8.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Artivion

Several hedge funds and other institutional investors have recently bought and sold shares of AORT. Champlain Investment Partners LLC bought a new stake in Artivion during the third quarter worth approximately $17,912,000. Goldman Sachs Group Inc. lifted its position in shares of Artivion by 144.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock valued at $24,510,000 after acquiring an additional 317,518 shares during the last quarter. Two Sigma Investments LP boosted its stake in shares of Artivion by 235.5% during the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after acquiring an additional 313,446 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Artivion by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after acquiring an additional 232,424 shares in the last quarter. Finally, Loomis Sayles & Co. L P grew its holdings in shares of Artivion by 35.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 840,062 shares of the company’s stock worth $38,315,000 after acquiring an additional 217,860 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 beat — Artivion reported Q4 EPS of $0.17 versus the $0.14 consensus and revenue of $118.3M (above estimates), with quarterly revenue up ~19% year-over-year. This confirms continued top-line momentum. Read More.
• Positive Sentiment: Full-year revenue growth — GAAP revenue rose to $441.3M for FY2025 from $388.5M in FY2024, signaling sustained recovery/expansion in sales. Read More.
• Positive Sentiment: FY2026 revenue guidance modestly above street — management guided revenue to $486.0M–$504.0M (consensus ~$491.1M), which implies a midpoint slightly ahead of estimates and supports continued top-line growth. Read More.
• Neutral Sentiment: Earnings call materials/transcript posted — the full Q4 earnings call transcript and slide deck are available for detail on segment performance and cadence. Useful for investors wanting management color. Read More.
• Negative Sentiment: Analyst price-target trim — Canaccord cut its AORT price target from $51 to $48 while keeping a “buy” rating; the cut reduces near-term analyst upside and may have pressured sentiment. Read More.
• Negative Sentiment: EPS guidance unclear/omitted — the company’s release/summary lacked clear EPS guidance (the EPS figure was not provided in the guidance summary), which can create uncertainty even with revenue guidance in place. Read More.
• Negative Sentiment: Large-volume sell-off — shares moved lower on unusually high volume versus average, indicating stronger selling pressure that amplified the price reaction to mixed news. Read More.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.